Merck & Co., Inc.
MRK Healthcare Drug Manufacturers General
Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024. In the quarter to June 2026, revenue grew 5.07%, EPS fell 130.7%, free cash flow grew 77.0% and total debt rose 50.4%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for five.
Follow MRK
Merck & Co., Inc. (MRK) Free cash flow margin
Merck & Co., Inc.'s free cash flow margin over the twelve months to 30 June 2026 was 24.1%, up 5.1 percentage points from fiscal 2025 (19.0%). Over the past ten years it has ranged from 7.68% (fiscal 2020) to 28.5% (fiscal 2015); the current reading is higher than 55% of that period. That is above the Drug Manufacturers General industry median of 17.2% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Embed this chart
Annual newest first
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 19.0% | (9.19) |
| FY2024 | 28.2% | 12.99 |
| FY2023 | 15.2% | (9.60) |
| FY2022 | 24.8% | 7.00 |
| FY2021 | 17.8% | 10.13 |
| FY2020 | 7.68% | (6.42) |
| FY2019 | 14.1% | (5.54) |
| FY2018 | 19.6% | 8.27 |
| FY2017 | 11.4% | (10.64) |
| FY2016 | 22.0% | (6.49) |
Against its own ten years
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| GILD Gilead Sciences, Inc. compare | 42.5% |
| ABBV AbbVie Inc. compare | 28.3% |
| NVS Novartis AG compare | 26.8% |
| AMGN Amgen Inc. compare | 26.7% |
| MRK Merck & Co., Inc. | 24.1% |
| PFE Pfizer Inc. compare | 17.3% |
| NVO Novo Nordisk A/S compare | 14.8% |
| AZN AstraZeneca PLC compare | 10.2% |
| JNJ Johnson & Johnson compare | 0.00% |
| Drug Manufacturers General industry median | 17.2% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on MRK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement